The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic) was found to demonstrate no increased risk of suicidal ideation in patients with obesity or type 2 diabetes, according to retrospective analyses of electronic health records examining these patient populations, published in Nature Medicine. Researchers’ analysis of 240,618 patients who were overweight/obese showed that those taking semaglutide had a significantly lower risk (0.11%) of suicidal ideation compared with those using non-GLP-1 anti-obesity medications (0.43%). In …
Read More